^
Association details:
| Biomarker: | BCR-ABL1 fusion |
|---|---|
| Cancer: | B Acute Lymphoblastic Leukemia |
| Drug: | Iclusig (ponatinib) (Multi-tyrosine kinase inhibitor) + Blincyto (blinatumomab) (CD3 agonist, CD19 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PONATINIB AND BLINATUMOMAB IN RELAPSED/REFRACTORY PHILADELPHIA-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA OR CHRONIC MYELOID LEUKEMIA IN LYMPHOID BLAST PHASE: SUBGROUP ANALYSIS FROM A PHASE II TRIAL
Published date:
05/11/2023
Excerpt:
We evaluated the efficacy and safety of blinatumomab and ponatinib in pts with R/R Ph+ ALL or CML-LBP….Among the 14 pts with R/R Ph+ ALL, 1 was in CR but with detectable BCR::ABL1 at enrollment. The rate of CR/CRiwas 92% (12 of 13 pts), with CR in 11 (85%) pts....Our results show that the combination of blinatumomab and ponatinib represent an effective chemotherapy-free regimen for pts with R/R Ph+ ALL and CML-LBP, with a favorable safety profile.
Secondary therapy:
Mini-HCVD
Source:
Title:
A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY
Published date:
05/11/2023
Excerpt:
We evaluated the chemotherapy-free approach of ponatinib and blinatumomab in patients with newly diagnosed Ph+ ALL….The chemotherapy-free combination of ponatinib and blinatumomab results in high rates of CMR and NGS MRD negativity. Encouraging duration of remission and survival has been observed without the need for SCT.
Source:
Title:
A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Published date:
05/26/2022
Excerpt:
Among 23 pts with ND Ph+ ALL evaluable for response, 22 (96%) achieved CR/Cri...The 2-year EFS and OS rates for the R/R cohort are 42% and 61%, and for the CML-LBP cohort are 33% and 60%, respectively….The chemotherapy-free combination of ponatinib and blinatumomab was safe and effective in Ph+ ALL and CML-LBP.
DOI:
10.1200/JCO.2022.40.16_suppl.7009
Trial ID:
Source:
Title:
Relapsed Philadelphia Chromosome-Positive Pre-B-ALL after CD19-Directed CAR-T Cell Therapy Successfully Treated with Combination of Blinatumomab and Ponatinib
Excerpt:
Herein, we describe a patient with Philadelphia chromosome-positive B-ALL who relapsed after CD19-directed CAR-T therapy, but subsequently responded to the combination of blinatumomab and the tyrosine kinase inhibitor ponatinib, with the achievement of a complete remission lasting 12 months.
DOI:
10.1159/000495558.
